Program
Autologous Tumor Infiltrating Lymphocytes LM103
Also written as “LM103”, “LM103 TILs Injection” and “Autologous tumor infiltrating lymphocytes (TILs)”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung, led by Suzhou BlueHorse Therapeutics.
Drug pageAutologous Tumor Infiltrating Lymphocytes LM103: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou BlueHorse Therapeutics | 77 open or running | phase 2since Dec 16, 2025 | May 5, 2022 | Dec 31, 2027phase 2 · NCT07310784 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2022First study: phase 1 study in MelanomaFirst studyNCT05366478 · 15 planned · China
- Jun 26, 2023Early phase 1 study in Solid TumorNCT05941936 · 5 planned · China
- Jul 12, 20232 early phase 1 studies in Solid TumorNCT05971589, NCT05971576
- Nov 15, 2024Early phase 1 study in Solid CancerNCT06697665 · 10 planned · China
- Dec 16, 2025Phase 2 study in Advanced MelanomaPhase 2 reachedNCT07310784 · 92 planned · China
- Feb 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07444437 · 45 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07444437
- Dec 31, 2027Primary completion: phase 2 study in Advanced MelanomaNCT07310784
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07444437Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Dec 31, 2027 | 45 |
| NCT07310784Advanced Melanoma · China | 2 | Recruiting | Dec 31, 2027 | 92 |
| NCT06697665Solid Cancer · China | Early 1 | Recruiting | Jan 2026 | 10 |
| NCT05971589Solid Tumor | Early 1 | Not yet recruiting | Apr 2026 | 5 |
| NCT05971576Solid Tumor | Early 1 | Not yet recruiting | Apr 2026 | 20 |
| NCT05941936Solid Tumor · China | Early 1 | Recruiting | Feb 2025 | 5 |
| NCT05366478Melanoma · China | 1 | Recruiting | May 30, 2024 | 15 |
How it is read
Names in the registry
- “LM103”, 4 entries
- “LM103 TILs Injection”, 2 entries
- “Autologous tumor infiltrating lymphocytes (TILs)”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.